Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;13(5):491-6.
doi: 10.1016/j.jacr.2015.11.016. Epub 2016 Jan 14.

Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer

Affiliations

Trends in the Use of (18)F-Fluorodeoxyglucose PET Imaging in Surveillance of Non-Small-Cell Lung and Colorectal Cancer

Christine M Veenstra et al. J Am Coll Radiol. 2016 May.

Abstract

Purpose: Surveillance PET after curative-intent treatment of non-small-cell lung cancer (NSCLC) or colorectal cancer (CRC) is not clearly supported by available evidence or the Choosing Wisely campaign. However, the frequency of PET imaging during the surveillance period is relatively unknown.

Methods: Using Surveillance, Epidemiology, and End Results-Medicare data, 65,748 patients aged 66 years or older who were diagnosed with stage I to IIIA NSCLC or stage I to III CRC from 2001 through 2009 and who underwent surgical resection were identified. Trends in "any PET" or "PET-only" use 6 to 18 months postoperatively were assessed.

Results: Any PET use more than doubled over the study period. Eleven percent of patients with NSCLC and 4% of those with CRC diagnosed in 2001 received any PET, compared with 25% of patients with NSCLC and 13% of those with CRC in 2009 (P < .001 for both). Higher stage disease was correlated with higher PET utilization and faster growth in use over the study period. PET-only use also increased over the study period, especially in higher stage disease. Fewer than 2% of patients diagnosed with stage IIIA NSCLC in 2001 received PET only, compared with 15% of patients diagnosed in 2009 (P = .014). Similarly, 1% of patients diagnosed with stage III CRC in 2001 received PET only, compared with 8% of patients diagnosed in 2009 (P < .001).

Conclusions: PET utilization during the surveillance period increased between 2001 and 2009. Further research is needed to determine the factors driving use of surveillance PET and to examine relationships between PET and patient outcomes.

Keywords: Choosing Wisely; FDG-PET; Positron emission tomographic imaging; colorectal cancer; non–small-cell lung cancer; surveillance.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Adjusted PET Surveillance in Non-Small Cell Lung Cancer, by Disease Stage, 2001–2009
Models adjust for patient age, sex, race/ethnicity, marital status, Charlson comorbidity index, and ZIP-Code level median household income in 2000. In these stacked area graphs, the red crosshatches indicate “PET only” and the blue stripes indicate PET with additional imaging. Their sum indicates “any PET.”
Figure 2.
Figure 2.. Adjusted PET Surveillance in Colorectal Cancer, by Disease Stage, 2001–2009
Models adjust for patient age, sex, race/ethnicity, marital status, Charlson comorbidity index, and ZIP-Code level median household income in 2000. In these stacked area graphs, the red crosshatches indicate “PET only” and the blue stripes indicate PET with additional imaging. Their sum indicates “any PET.”

References

    1. Patel K, Hadar N, Lee J, et al.: The lack of evidence for PET or PET/CT surveillance of patients with treated lymphoma, colorectal cancer, and head and neck cancer: a systematic review. J Nucl Med 54:1518–27, 2013 - PMC - PubMed
    1. Meyerhardt JA, Mangu PB, Flynn PJ, et al.: Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31:4465–70, 2013 - PubMed
    1. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology. Version 2.2015. Colon cancer, 2015 - PubMed
    1. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology. Version 4.2015. Non-small cell lung cancer, 2015 - PubMed
    1. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology. Version 2.2015. Rectal cancer, 2015 - PubMed

MeSH terms

Substances